Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P830055/S351

Attune Revision Knee System

Depuy, Inc. · Decision date Sep 21, 2026

MEDTECHLEDGER EXPLANATIONP830055/S351

What did the FDA approve?

The FDA record lists approval of supplement P830055/S351 for DePuy, Inc.'s Attune Revision Knee System, filed under the Normal 180 Day Track with the reason Change Design/Components/Specifications/Material. Because the identifier ties this supplement to PMA P830055, it modifies that existing approval for the device category Prosthesis, knee, patellofemoral-tibial, semi-constrained, metal/polymer, mobile bearing; it is not an approval of a new device.

The statement covers two changes to the Attune Revision CRS Rotating Platform (CRS RP) tibial insert components: adding ram extrusion as an alternative to compression molding for the AOX UHMWPE bar stock material, and replacing single high-dose sterilization with a split-dose method combining raw-material crosslinking and final terminal sterilization. The record gives no test data, sterilization doses, or clinical or safety conclusions, and its stated purpose is not independent proof of safety or effectiveness.

FDA approval order statement

approval for the following two changes for the Attune Revision CRS Rotating Platform (CRS RP) tibial insert components of the Attune Revision Knee System:i. change in the manufacturing consolidation process to add ram extrusion as an alternative to compression molding for bar stock material antioxidant (Pentaerythritol tetrakis [3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate]) (AOX), Ultra-High Molecular Weight Polyethylene (UHMWPE) material of the aforementioned components.ii. change in sterilization dose from a single, high dose sterilization to a split-dose sterilization method through a combination of crosslinking AOX UHMWPE raw material and final terminal sterilization of the aforementioned components.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Orthopedic
Decision date
Sep 21, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P830055/S351
Regulatory pathway
PMA supplement
Applicant
Depuy, Inc.
Product code
NJL
Decision code
APPR
Decision date
Sep 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing.

Applicant
Depuy, Inc.
Product code
NJL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P830055/S351 received

    Application receipt date recorded by FDA.

  2. P830055/S374 · Related supplement

    LCS(R) TOTAL KNEE SYSTEM, specifically ATTUNE Cruciate Retaining (CR), Posterior Stabilized (PS) and Revision Femoral C

  3. P830055/S372 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Cementless Rotating Platform (RP) Knee System, ATTUNE Revision R

  4. P830055/S376 · Related supplement

    Attune Rotating Platform (RP) Total Knee System and the DePuy P.F.C. Sigma Rotating Platform (RP) Total Knee System an

  5. P830055/S351 · FDA decision

    Normal 180 Day Track

  6. P830055/S377 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Revision Rotating Platform (RP) Total Knee System, and M.B.T. Re

  7. P830055/S379 · Related supplement

    ATTUNE Revision Knee System

  8. P830055/S381 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, and ATTUNE Revision Rotating Platform (RP) Knee System

Timeline entries are records held by MedtechLedger for P830055. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P830055

Explore the linked device profile

Other records with product code NJL

Product / regulatory recordCompanyPathwayDecision dateSource
Zimmer, Inc.PMA supplementOct 16, 2026FDA
Zimmer, Inc.PMA supplementSep 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Depuy, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
P.O. Box 988, 700 Orthopaedic Dr., Warsaw, IN, 46581

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records